Impel Pharmaceuticals is a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with unmet medical needs, with an initial focus on the Central Nervous System. Co. has launched Trudhesa for the acute treatment of migraine headaches with or without aura in adult patients. Co. is developing several product candidates, including INP105 for the acute treatment of agitation and aggression in patients with Autism Spectrum Disorder. Co.'s pipeline of proprietary product candidates also includes INP107 for the treatment of OFF episodes in Parkinson's Disease. The IMPL average annual return since 2021 is shown above.
The Average Annual Return on the IMPL average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether IMPL average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the IMPL average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|